Education/ACR/EULAR

artificial intelligence machine learning computer

AI in RA: the story grows along the patient pathway

Antoni Chan, MD, PhD
Jun 02, 2023

The use of artificial intelligence to analyse large data sets using its subset component machine learning has taken centre stage recently in the management of rheumatic conditions including rheumatoid arthritis. The use of AI is now starting to cross the various stages in patient care from

Read Article
Reflections on COVID-19 and autoimmunity: post-vaccination autoimmunity is not specific to COVID-19, autoimmunity is not autoimmune disease, the large numbers may result in the perception of increased occurrence of autoimmunity, Schulze-Koops H, COVID-19, #EULAR2023 @RheumNow https://t.co/Rm9OEWrBzo
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 02, 2023
The modern day poster tour #EULAR2023: the posters & speakers come to you, broadcast through a headset (it’s almost like a silent disco, in a hall with lots of background noise). Definite innovation but at capacity, wish more people could tune in on their own devices @RheumNow https://t.co/sOXnYctsfN
David Liew @drdavidliew( View Tweet )
Jun 02, 2023
A shame. Pts with #scleroderma are dying waiting for organ transplant- we should list and work them up for Tx earlier. PAH Pts May do worse @eular_org #EULAR2023 @RheumNow OP0241 https://t.co/8ZlHJmETGA
Janet Pope @Janetbirdope( View Tweet )
Jun 02, 2023
Let le introduce you to ARTHUR 🤖 A very skilled robot who scans your hands and wrists in 15 mn 🤚 Amazing to see new #AI developments that will make our lifes’ easier! #EULAR23 @ROPCA3 @JustSoren Stand M6 @RheumNow https://t.co/7PtR2CGqTt
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 02, 2023
Should we use #immunesuppression EARLY in #scleroderma to prevent #ILD? Answer from a study comparing Y vs N immune suppression- there was no difference in FVC decline. Maybe not a long enough study, ? Chanelling bias scleroderma #lung #disease OP0239 @RheumNow #EULAR2023

Janet Pope @Janetbirdope( View Tweet )

Jun 02, 2023
#ClinicalPearl Rx of #scleroderma #ILD -add another drug. MMF, then Cyclo, Rituximab, ?tocilizumab; if progressive fibrosis then #Nintedanib ?Pirfenidone Small RCT of MMF v Tacrolimus - looked the same -helpful if MMF fails, future pregnancy OP0240 @RheumNow #EULAR2023 @eular_org https://t.co/XWphyEO2JJ
Janet Pope @Janetbirdope( View Tweet )
Jun 02, 2023
An AI algorithm to predict opined related deaths UK database >1000000 pts, 1200+ opioids related deaths Risk factors: Substance used disorder Hx self harm Alcohol abuse Oxycodone Liver disease Concomitant gabapentinoids & BZD *no pictures allowed* @Rheumnow OP0269 #EULAR23 https://t.co/II96fnhqy3
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 02, 2023
Risks for #ILD #SSc lung progression. FVC decline >5% is the gold standard but there are other criteria. OP0236 #EULAR2023 @RheumNow @eular_org #scleroderma Some criteria are stricter - larger PFT changes and/or worsening symptoms or fibrosis, so depends on def’n for % def’n https://t.co/TCuX2KY64w
Janet Pope @Janetbirdope( View Tweet )
Jun 02, 2023
Very much looking forward to our joint PRP-HRP-Rheum session later today How to improve & implement apps for self management in clinical care @ElenaNikiUK @fibrofella @ProfYelizPrior We will discuss and reveal the results of a survey made for #EULAR23 @RheumNow @eular_org https://t.co/R5vTW3FeWO
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 02, 2023
acr_session2.jpeg

EULAR 2023 – Day 2 Report

Jack Cush, MD
Jun 01, 2023

Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial

Read Article
RheumNow Eular 2023 Daily Recap Series https://t.co/oZXuyv8wL5

Links:

Dr. John Cush @RheumNow( View Tweet )

Jun 01, 2023
question-mark-1872634_640.jpg

Better at Predicting RA from MRI: Humans or Computers?

David Liew
Jun 01, 2023

An artificial intelligence model to assess pre-RA hand MRIs has confirmed what human readers have known before: that bone marrow edema and tenosynovitis are objectively the best predictors of future RA development in patients with clinically suspect arthralgias or undifferentiated arthritis

Read Article
Stills,continuum

AOSD: Young vs. Elderly Onset

Bella Mehta, MBBS, MS
Jun 01, 2023

Adult onset still's disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million. Traditionally, a bimodal distribution by age has been

Read Article
Always great to have @EMA_News to come and to talk to us at #EULAR2023 Our meds are very important to us, and the more we can understand how decisions are made and RWE is collected, the better 👍 @RheumNow https://t.co/hSutraUsFD
David Liew @drdavidliew( View Tweet )
Jun 01, 2023
• Erdheim-Chester disease (ECD) is associated with Langerhans cell histiocytosis (LCH) • Bone pain, xanthelasma, hairy kidney • Differential diagnoses of LCH • BRAF mutation associated with cardiac and neurological phenotype of ECD Haroche J, Papo M #EULAR2023 @RheumNow https://t.co/AzKJKp82nq
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 01, 2023
Do we use too much PNL in GCA (when not using TCZ)? Could we wean quicker? Salvarini group n=22 26w PNL weaning protocol from GiACTA, but no TCZ 10/26 in relapse free remission at 1y Much less PNL, still some steroid AEs Way of the future for some? POS0728 #EULAR2023 @RheumNow https://t.co/qeZHeCi9vq
David Liew @drdavidliew( View Tweet )
Jun 01, 2023
You need to see this! Albert with a Left V1 distribution of #shingles is a ‘bot’ who interacts with #rheumatologists at #EULAR2023 ⁦@RheumNow⁩ ⁦@eular_org⁩ #artificial #intelligence https://t.co/gDwzc3NX7v
Janet Pope @Janetbirdope( View Tweet )
Jun 01, 2023
#EULAR2023 #POS0627 Researchers in Manchester identified several proteins associated with subclinical cardiovascular abnormalities on Cardiac MRI in Scleroderma using proteomics. Need validation. Could be useful for stratification and identify therapeutic targets @RheumNow https://t.co/55eNGhMu5f
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 01, 2023
#EULAR2023 #POS0618 This is cool! Researchers from Switzerland are developing new Quantitative Radiomic Risk Score (from HRCT) to stratify response to Anti-Fibrotic in #ILD. Data presented in pre-clinical study & paralleled molecular effects. Human study is in progress @RheumNow https://t.co/qAsWew4FEO
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 01, 2023
Are we going to treat hands OA with MTX? Moderate effect on VAS pain at 6 and 12 months in a small RCT vs. PBO in hands OA WITH MRI detected synovitis. Thoughts 1) Is it really OA? 2) Benefit Risk balance remains debatable @RheumNow OP0070 #EULAR23 https://t.co/WLlX48NtGT
Aurelie Najm @AurelieRheumo( View Tweet )
May 31, 2023
#CPPD and #cervical involvement. Several clinical presentations A-asymptomatic deposition B-crowned dens syndrome C-retro-odontoid pseudotumor D-inflammatory discitis Good teaching points in the supplements! @RheumNow #EULAR2023 Abst#AB1859 https://t.co/LJe7Gk1oZX
Bella Mehta @bella_mehta( View Tweet )
May 31, 2023
#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed: - 1 in 10 people had AID in the last 20yrs - socioeconomic, seasonal & regional disparities cd influence pathogenesis - CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
May 31, 2023
hip.THR_.jpg

EULAR 2023 – Day 1 Report

Jack Cush, MD
May 31, 2023

EULAR 2023 launched today to crowds of attendees.  The opening Plenary session and presidential address by Dr. Ian McInnes was followed by a number of overview and review sessions with but a half-day of abstracts presentations, on several therapeutic areas including osteoarthritis, JIA, COVID

Read Article
arthritis.RA_.Xray_.hands_.jpg (keep)

An update on JAK inhibitors and cardiovascular risks

Antoni Chan, MD, PhD
May 31, 2023

In the last 2 years, there has been more caution and vigilance with the use of JAK inhibitors in the treatment of rheumatoid arthritis due to the risk of CV events, including MACE and VTE. The ORAL surveillance study, a post-approval safety study conducted in RA patients aged ≥50 years with ≥1

Read Article

Recent Blogs

ICYMI: The Biosimilar "Buy In"

Rachel Tate, DO
May 29, 2023
Biosimiars
The landscape of biosimilars is vast. This year alone we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients.  Drs. Jack Cush and Arthur Kavanuagh shared insights into these key discussions during RheumNow Live 2023. Read Post

    Do you get our email newsletter?

    Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

    Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

    Copyright 2023 All Rights Reserved.

    ×